ACRV Stock Financials: Financial Performance and Reports

Period	FY-2023	FY-2022	FY-2021	FY-2020
Period Ended	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Operating Revenue	$0.00	$0.00	$0.00	$0.00
Cost of Revenue	$536,000.00	$1.10 M	$832,000.00	$13,000.00
Gross Profit	-$536,000.00	-$1.10 M	-$832,000.00	-$13,000.00
Gross Profit Ratio	0	0	0	0
Research and Development Expenses	$45.49 M	$23.95 M	$13.72 M	$1.87 M
General & Administrative Expenses	$21.08 M	$8.71 M	$2.47 M	$1.30 M
Selling & Marketing Expenses	$134,000.00	$0.00	$0.00	$0.00
Selling, General & Administrative Expenses	$21.21 M	$8.71 M	$2.47 M	$1.30 M
Other Expenses	$0.00	$1.49 M	-$59,000.00	-$2.14 M
Operating Expenses	$66.70 M	$32.66 M	$16.18 M	$3.17 M
Cost And Expenses	$67.24 M	$32.66 M	$16.18 M	$3.17 M
Interest Income	$0.00	$0.00	$0.00	$0.00
Interest Expense	$0.00	-$1.49 M	$0.00	$0.00
Depreciation & Amortization	$536,000.00	$364,000.00	$37,000.00	$13,000.00
EBITDA	-$66.70 M	-$32.66 M	-$16.15 M	-$3.16 M
EBITDA Ratio	0	0	0	0
Operating Income	-$67.24 M	-$32.66 M	-$16.18 M	-$3.17 M
Operating Income Ratio	0	0	0	0
Total Other Income/Expenses Net	$6.85 M	$1.49 M	-$59,000.00	-$2.14 M
Income Before Tax	-$60.39 M	-$31.17 M	-$16.24 M	-$5.31 M
Income Before Tax Ratio	0	0	0	0
Income Tax Expense	$1.00	-$1.49 M	$0.00	$0.00
Net Income	-$60.39 M	-$29.68 M	-$16.24 M	-$5.31 M
Net Income Ratio	0	0	0	0
EPS	-2.74	-1.35	-0.78	-0.25
EPS Diluted	-2.74	-1.35	-0.78	-0.25
Weighted Average Shares Out	$22.08 M	$21.92 M	$20.86 M	$20.86 M
Weighted Average Shares Out Diluted	$22.08 M	$21.92 M	$20.86 M	$20.86 M
Link

Acrivon Therapeutics, Inc. Common Stock (ACRV) Financials